Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-11-15
pubmed:abstractText
NXL104 is a potent inhibitor of class A and C serine ?-lactamases, including KPC carbapenemases. Native and NXL104-inhibited TEM-1 and P99 ?-lactamases analyzed by liquid chromatography-electrospray ionization-time of flight mass spectrometry revealed that the inactivated enzymes formed a covalent adduct with NXL104. The principal inhibitory characteristics of NXL104 against TEM-1 and P99 ?-lactamases were determined, including partition ratios, dissociation constants (K), rate constants for deactivation (k(2)), and reactivation rates. NXL104 is a potent inhibitor of TEM-1 and P99, characterized by high carbamylation efficiencies (k(2)/K of 3.7 × 10(5) M(-1) s(-1) for TEM-1 and 1 × 10(4) M(-1) s(-1) for P99) and slow decarbamylation. Complete loss of ?-lactamase activity was obtained at a 1/1 enzyme/NXL104 ratio, with a k(3) value (rate constant for formation of product and free enzyme) close to zero for TEM-1 and P99. Fifty percent inhibitory concentrations (IC(50)s) were evaluated on selected ?-lactamases, and NXL104 was shown to be a very potent inhibitor of class A and C ?-lactamases. IC(50)s obtained with NXL104 (from 3 nM to 170 nM) were globally comparable on the ?-lactamases CTX-M-15 and SHV-4 with those obtained with the comparators (clavulanate, tazobactam, and sulbactam) but were far lower on TEM-1, KPC-2, P99, and AmpC than those of the comparators. In-depth studies on TEM-1 and P99 demonstrated that NXL104 had a comparable or better affinity and inactivation rate than clavulanate and tazobactam and in all cases an improved stability of the covalent enzyme/inhibitor complex.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-10625455, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-10873536, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-11092545, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-11114163, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-1436034, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-14609325, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-15254025, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-1544485, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-15674842, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-15700950, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-15872044, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-16041072, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-17261621, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-17274971, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-17630699, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-18324783, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-18689875, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-18824507, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19161282, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19493866, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19514910, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19528274, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19554599, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19736945, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-19747143, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-20008772, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-20036536, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-20065329, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-20099888, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-3038122, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-358199, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-358200, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-4553144, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-6332621, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-6606712, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-6984651, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-8204611, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-8243630, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-8388201, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-8394311, http://linkedlifedata.com/resource/pubmed/commentcorrection/20921316-879738
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1098-6596
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5132-8
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
pubmed:affiliation
Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France.
pubmed:publicationType
Journal Article